Herein, we describe a case in which a patient with relapsed and refractory APL failed to undergo treatment with ATRA in combination with arsenic trioxide (ATO) and chemotherapy, but she achieved a complete hematologic response (CHR) with a Bcl-2 inhibitor. This evidence concerns the gene BCL2 and acute promyelocytic leukemia.